You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

Evaluation of 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in rat models with hepatocellular carcinoma with liver cirrhosis

Issue title: Frontiers in Biomedical Engineering and Biotechnology – Proceedings of the 4th International Conference on Biomedical Engineering and Biotechnology, 18–21 August 2015, Shanghai, China

Guest editors: Feng Liu, Dong-Hoon Lee, Ricardo Lagoa and Sandeep Kumar

Article type: Research Article

Authors: Park, S.I.a | Lee, J.H.b | Ham, H.J.a | Jung, Y.J.a | Park, M.S.a | Lee, J.c | Maeng, L.S.a | Chung, Y.A.a; d | Jang, K.S.a; e; *

Affiliations: [a] Institute of Catholic Integrative Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Incheon 403-720, The Republic of Korea | [b] Laboratory of Molecular Pathology, Department of Pharmacy, College of Pharmacy, Seoul National University, Seoul 151-742, The Republic of Korea | [c] Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, USA | [d] Department of Radiology, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Incheon 403-720, The Republic of Korea | [e] Department of Neurosurgery, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Incheon 403-720, The Republic of Korea

Correspondence: [*] Address for correspondence: K.S. Jang, Institute of Catholic Integrative Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Incheon 403-720, The Republic of Korea. Tel.: 82-32-280-5243; Fax: 82-32280-5244; E-mail: [email protected].

Note: [1] S.I. Park and J.H. Lee contributed equally to this paper.

Keywords: Hepatocellular carcinoma, PET/CT, 18F-FDG

DOI: 10.3233/BME-151466

Journal: Bio-Medical Materials and Engineering, vol. 26, no. s1, pp. S1669-S1676, 2015

Published: 2015
Get PDF open access

Liver cirrhosis is a predominant risk factor for hepatocellular carcinoma (HCC). However, the exact mechanism of the progression from cirrhosis to cancer remains unclear. The uptake of 2-[18F]-fluoro-2-deoxy-D-glucose (18F-FDG) is widely used as a marker of increased glucose metabolism to monitor the progression of cancer with positron emission tomography (PET)/computed tomography (CT). Here we investigated the feasibility of using 18F-FDG PET/CT in the diethylnitrosamine (DEN) mediated experimental hepatocellular carcinoma model. Rats received weekly intraperitoneal injections of DEN for 16 weeks for induction of HCC. We recorded starting from 0 days or 0 weeks after the last DEN injection. The weight and survival rate of rats were then measured. Also, an 18F-FDG PET scan and serum analysis were performed at minus 2, 0, plus 2, and plus 4 weeks after the last DEN injection. The body weight of rats was maintained between 350 g and 370 g during 14 and 20 weeks, and the rats were euthanized at 35 days after the last DEN injection. The serum levels of alanine transaminase (ALT), aspartate transaminase (AST), and alkaline phosphate (ALP) were significantly higher at zero weeks after the last DEN injection. The 18F-FDG uptake for the quantitative evaluation of HCC was done by measuring the region of interest (ROI). At minus two weeks after the last DEN injection, the ROI of rats had significantly increased compared to the normal group, in a time-dependent manner. These results suggest that FDG uptake serves as a good screening test to evaluate the feasibility of DEN-induced HCC.

Show more